Prospective Study to Identify Efficacy, Safety, and Predictors of Tezepelumab in Severe Asthma

Prospective Study to Identify Efficacy, Safety, and Predictors of Tezepelumab in Severe Asthma - J-EAST

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000049566

Enrollment

Registered

2022-11-20

Start date

2022-11-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

asthma, bronchial asthma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients diagnosed with severe asthma according to the Comprehensive Allergy Guidelines 2022 2) Patients with severe bronchial asthma who are using high-dose inhaled steroids and long-acting beta2-stimulants 3) Patients who give written consent to participate in this study 4) Patients 20 years of age or older

Exclusion criteria

Exclusion criteria: 1) Patients with a history of previous administration of tezepelumab (2) Patients with serious complications such as cardiac, hepatic, or renal disease (3) Patients who are judged to be inappropriate for the subject by the physician's judgment.

Design outcomes

Primary

Measure	Time frame
Predictors of efficacy before treatment and improvement in symptoms after 16 weeks	—

Countries

Japan

Contacts

Public ContactTakehiro Izumo

Japanese Red Cross Medical Center Respiratory Medicine

drtake1118@gmail.com03-3400-1311

Outcome results